A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

Official title

A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, and Efficacy of AMG 732 in Healthy Subjects and Subjects With Moderate-to-Severe Active Thyroid Eye Disease

Overview

The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses. The primary objective of Part B of this study is to investigate the efficacy of AMG 732 in participants with Thyroid Eye Disease (TED) after multiple SC doses.

Detailed description

Recruitment has ended for the Phase 1 portion of the study and will reopen when Phase 2 begins recruitment.

Interventions

• Drug AMG 732
  SC injection
• Other Placebo
  SC injection

Primary outcome measures

• Part A: Number of Participants With Treatment-emergent Adverse Events [Time frame: Day 1 through Week 36 (End of Study)]
• Part B: Change from Baseline in Proptosis Measurement by an Exophthalmometer in the Study Eye [Time frame: Baseline to End of Treatment (EoT) (approximately 6 Months)]

Secondary outcome measures (12)

• Part A: Maximum Observed Plasma Concentration (Cmax) of AMG 732 [Time frame: Up to Week 36]
• Part A: Time to Cmax (Tmax) of AMG 732 [Time frame: Up to Week 36]
• Part A: Area Under the Plasma Concentration-time Curve (AUC) of AMG 732 [Time frame: Up to Week 36]
• Part A: Half-life (t1/2) of AMG 732 [Time frame: Up to Week 36]
• Part A: Number of Participants With Anti-drug Antibodies (ADAs) [Time frame: Up to Week 36]
• Part B: Number of Participants With Treatment-emergent Adverse Events [Time frame: Up to Week 48]
• Part B: Cmax of AMG 732 [Time frame: Up to Week 48]
• Part B: Tmax of AMG 732 [Time frame: Up to Week 48]
• Part B: AUC of AMG 732 Over the Dosing Interval [Time frame: Up to Week 48]
• Part B: Accumulation of AMG 732 Following Multiple Dosing [Time frame: Up to Week 48]
• Part B: Half-life (t1/2) of AMG 732 [Time frame: Up to Week 48]
• Part B: Number of Participants With Anti-drug Antibodies (ADAs) [Time frame: Up to Week 48]

Eligibility criteria

Inclusion criteria for Part A/Phase 1 only:

• Participant has provided informed consent before initiation of any study-specific activities/procedures.
• Male or female aged 18 to 55 years (Part A).
• Female participants must be of non-childbearing potential.
• Body mass index (BMI) between 18 and 30 kg/m\^2, inclusive, at screening.
• The participant has adequate venous access and can receive intravenous (IV) therapy.
• The participant is considered by the investigator or designee to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead electrocardiogram (ECG) results, and physical examination findings at screening.
• Healthy Japanese participants in cohort 4 only. Japanese participants must meet all the following as confirmed by interview: Descendants of 4 ethnic Japanese grandparents who were born in Japan; Both parents are ethnic Japanese who were born in Japan; Hold a Japanese passport or identity papers; Have lived outside Japan for less than 10 years at the time of screening and lifestyle including diet has not changed significantly since leaving Japan.

Inclusion criteria for Part B/Phase 2 only:

• Male or female aged 18 to 65 years.
• Moderate-to-severe active TED.
• The participant had onset of active TED within 15 months prior to baseline.
• Clinical diagnosis of Graves' disease associated with active TED with a Clinical Activity Score (CAS)≥3 for the most severely affected eye at screening and baseline.
• Proptosis ≥18mm in the study eye at baseline.
• Participants with baseline subjective binocular diplopia score >0.
• Does not require immediate surgical ophthalmological intervention and is not planning corrective surgery/irradiation during the trial.

Exclusion criteria for Part A and Part B:

• Malignant condition in the past 12 months or major surgery within 8 weeks or plans to have an elective surgery from screening through end of study.
• Active liver or kidney disfunction at screening.
• Positive test for hepatitis B/C or Human immunodeficiency virus (HIV) serology at screening.
• Glycated hemoglobin (HbA1c) > 6.5% and/or fasting glucose levels> 126 mg/dL (> 7 mmol/L) at screening.
• Use of any steroid (IV, oral, steroid eye drops) within 3 weeks prior to the first dose. Steroids cannot be initiated during the trial. Exceptions include topical and inhaled steroids and steroids used to treat injection related reactions or short course of steroid for asthma control.
• Known hypersensitivity to teprotumumab or any other monoclonal antibody products.
• History of substance abuse within 12 months before screening.
• Donated blood, or had significant blood loss, or received a transfusion of any blood or blood products within 60 days prior to day 1 dosing or received a plasma donation within 7 days prior to day 1 dosing.

Exclusion criteria for PartA/Phase 1 only

• Blood pressure or ECG abnormalities at screening.

Exclusion criteria for Part B/Phase 2 only:

• Use of any steroid or other non-steroid immunosuppressive agent, monoclonal antibody, within 3 months prior to the first injection of study drug.
• Use of teprotumumab or any other IGF-1R inhibitor.
• Prior orbital irradiation or decompression in the study eye.
• History or existing inflammatory bowel disease (ulcerative colitis or Crohn's disease).

Other protocol-defined inclusion/exclusion criteria apply.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation

Randomized

Model

Sequential

Masking

Double blind

Primary purpose

Treatment

Study locations

United States · 12 centers

• Applied Research Center of Arkansas — Little Rock
• Amy Patel Jain MD — Newport Beach
• Levenson Eye Associates — Jacksonville
• Ilumina Medical Research — Kissimmee
• Sarasota Retina Institute — Sarasota
• Vision Medical Research, Inc. — Orland Park
• Massachusetts Eye and Ear Infirmary — Boston
• Ppd Las Vegas Research Unit — Las Vegas
• … and 4 more centers

Germany · 4 centers

• Universitaetsklinikum Essen — Essen
• Buergerhospital und Clementine Kinderhospital gGmbH — Frankfurt am Main
• Universitaetsklinikum Freiburg — Freiburg im Breisgau
• Universitaetsklinikum Leipzig AoeR — Leipzig

Italy · 4 centers

• Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico — Milan
• Azienda Ospedaliero Universitaria Pisana — Pisa
• Azienda Ospedaliero Universitaria Pisana — Pisa
• Azienda Socio Sanitaria Territoriale dei Sette Laghi — Varese

Japan · 4 centers

• Aichi Medical University Hospital — Nagakute-shi
• Hayashi Eye Hospital — Fukuoka
• Kozawa Eye Hospital And Diabetes Center — Mito
• University of Miyazaki Hospital — Miyazaki

Poland · 4 centers

• Profesorskie Centrum Medyczne Spolka z Ograniczona Odpowiedzialnoscia — Gdansk
• Uniwersyteckie Centrum Stomatologii I Medycyny Specjalistycznej Spzoo — Poznan
• Dc-Med Spolka z Ograniczona Odpowiedzialnoscia Spolka Komandytowa — Swidnica
• Eb Group Spolka z ograniczona odpowiedzialnoscia — Warsaw

Canada · 3 centers

• Vancouver General Hospital — Vancouver
• Santé Québec Est-de-l'Île-de-Montréal - Universitaire — Montreal
• CHU de Québec-Université Laval - CUO-Recherche Clinique, Hopital du Saint-Sacrement — Québec

Spain · 3 centers

• Hospital Universitario Virgen Macarena — Seville
• Hospital Universitario Ramon y Cajal — Madrid
• Hospital Universitari i Politecnic La Fe — Valencia

Australia · 2 centers

• Macquarie University — North Ryde
• North Shore Private Hospital — St Leonards

France · 2 centers

• Centre Hospitalier Universitaire de Nantes - Hopital Nord Laennec — Nantes
• Hopital Pitie-Salpetriere — Paris

Greece · 2 centers

• General Hospital of Athens Laiko — Athens
• Ippokratio General Hospital of Thessaloniki — Thessaloniki

Singapore · 2 centers

• National University Hospital — Singapore
• Singapore National Eye Centre — Singapore

Taiwan · 2 centers

• National Taiwan University Hospital — Taipei
• Taipei Veterans General Hospital — Taipei

Identifiers

NCT: NCT06401044 · 20230302

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗